Faecal microbiota transplantation for recurrent Clostridium difficile infection and beyond: Risks and regulation

Journal of Hospital Infection

Volumn 92, Issue 2, 2016, Pages 115-116

  Goldenberg, S D ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; VANCOMYCIN;

ASPIRATION PNEUMONIA; BIOENGINEERING; CLOSTRIDIUM DIFFICILE INFECTION; COLON PERFORATION; CONSENSUS DEVELOPMENT; DRUG EFFICACY; EDITORIAL; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTESTINE FLORA; LENGTH OF STAY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT INFECTION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); ADVERSE EFFECTS; CLOSTRIDIUM INFECTIONS; DIARRHEA; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RECURRENT DISEASE; RISK; SECONDARY PREVENTION; SOCIAL CONTROL;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; RECURRENCE; RISK; SECONDARY PREVENTION; SOCIAL CONTROL, FORMAL;

EID: 84958050310     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2015.12.004     Document Type: Editorial

References (25)

1. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431.
2. Cornely O.A., Crook D.W., Esposito R., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012, 12:281-289.
3. Vardakas K.Z., Polyzos K.A., Patouni K., et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012, 40:1-8.
4. Dubberke E.R., Olsen M.A. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012, 55(Suppl. 2):S88-92.
5. Le Monniet A., Duburq A., Zahar J.-R., et al. Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals. J Hosp Infect 2015, 91:117-122.
6. Goldenberg S.D., Brown S., Edwards L., et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis 2015 Dec 12, [Epub ahead of print]. 10.1007/s10096-015-2538-z.
7. Van Nood E., Vrieze A., Niewdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013, 368:407-415.
8. Bagdasarian N., Rao K., Malani P.N. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015, 313:398-408.
9. Drekonja D., Reich J., Gezahegn S, et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med 2015, 162:630-638.
10. Cammarota G., Masucci G.I., Bibbo S., et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015, 41:835-843.
11. Youngster I., Russell G.H., Pindar C., et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014, 58:1515-1522.
12. Kelly CR. A multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Abstract O44, American College of Gastroenterology Scientific Meeting, October 16th-21st, 2015, Hawaii, USA.
13. Zipursky J.S., Sidorsky T.I., Freedman C.A., Sidorsky M.N., Kirkland K.B. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012, 55:1652-1658.
14. Paramsothy S., Walsh A.J., Borody T., et al. Gastroenterologist perceptions of faecal microbiota transplantation. World J Gastroenterol 2015, 21:10907-10914.
15. Costello S.P., Tucker E.C., La Brooy J., Schoeman M.N., Andrews J.M. Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis 2015 Nov 30, pii: civ994 [Epub ahead of print]. 10.1093/cid/civ994.
16. Costello S.P., Conlon M.A., Vuaran M.S., Roberts-Thomson I.C., Andrews J.M. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Therapeut 2015, 42:1011-1018.
17. Youngster I., Russell G.H., Pindar C., Ziv-Baran T., Sauk J., Hohmann E.L. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014, 312:1772-1778.
18. Hamilton M.J., Weingarden A.J., Sadowski M.J., Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107:761-767.
19. Hirsch B.E., Saraiya N., Poeth K., Schwartz R.M., Epstein M.E., Honig G. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis 2015, 15:191.
20. Baxter M., Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect 2016, 92:117-127.
21. Parmasothy S., Borody T.J., Lin E., et al. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis 2015, 21:1600-1606.
22. Porter R.J., Fogg C. Faecal microbiota transplantation for Clostridium difficile infection in the United Kingdom. Clin Microbiol Infect 2015, 21:578-582.
23. Orenstein R., Dubberke E., Hardi R., et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis 2015, [Epub ahead of print]. 10.1093/cid/civ938.
24. Brandt L.J. Fecal microbiota transplant: respice, adspice, prospice. J Clin Gastroenterol 2015, 49:S65-S68.
25. Petroff E.O., Gloor G.B., Vanner S.J. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013, 1:3.